Peer reviewed publications reporting the effectiveness of the Kurve intranasal insulin product

Nasaldrugdeliveryblog.com opens lines of communication between drug delivery researchers, device manufacturers. The first blog to address issues related to nasal drug delivery formulation, research, delivery, and devices was launched by Kurve Technology, Inc., a leading developer of nasal drug delivery devices.

The blog — http://www.nasaldrugdeliveryblog.com — invites scientists, researchers and pharmaceutical executives to exchange and comment on clinical research, recently-published journal articles, events and conferences, and thought-provoking posts on systemic, topical, and nose-to-brain delivery.

“Our aim was to create an online forum for open communication in the nasal delivery industry,” said Marc Giroux, CEO of Kurve Technology. “Now academic researchers, pharmaceutical industry managers , and device professionals can interact every day rather then wait for the next conference or event. Pharmaceutical and trade media can also stay abreast of industry developments via the blog.”

Blog entries are authored by the executive team of Kurve Technology as well as guest contributors. Drug delivery professionals are encouraged to submit non-promotional posts at nasaldrugdeliveryblog.com.

About Kurve Technology, Inc. Kurve Technology, Inc. offers pharmaceutical companies innovative nasal delivery technologies for topical, systemic, nose-to-brain medical therapies and vaccines. Kurve’s Controlled Particle Dispersion (CPD)™ technology intranasally delivers formulations with far greater efficacy and efficiency than traditional methods. The ViaNase product line of intelligent atomizers incorporates CPD with the potential to deliver a wide range of formulations. Kurve Technology is headquartered in Bothell, WA with offices in Research Triangle Park, NC.

Sign Up Now to Invest With Kurve!

*Founders, board, and management own 51% of common shares

16825 48th West Suite 434
Lynnwood, WA 98037

info@kurvetx.com
(425) 640-9249

Transfer Agent: KoreConX Inc. | Broker-Dealer: Rialto Markets LLC | Escrow Agent: Wilmington Trust NA The Refund Policy: There are no refunds or cancelations of commitments once the subscription agreement is signed and submitted. Please contact compliace@rialtomarkets.com with questions regarding a cancelation or refund.

Rialto Markets LLC is the Onboarding Agent for this offering and is not an affiliate of nor connected with the Issuer.

Rialto Markets LLC is NOT placing or selling these securities on behalf of the Issuer.

Rialto Markets LLC is NOT soliciting this investment nor making any recommendations by collecting, reviewing, and processing your application for investment.

Rialto Markets LLC conducts Anti-Money Laundering, Identity, and Bad Actor Disqualification reviews of the Issuer, and ensures they are a registered business in good standing.

Rialto Markets LLC is NOT validating or approving the information provided by the Issuer or the Issuer itself.

Contact information below is provided for applicants to make inquiries and requests of Rialto Markets LLC regarding the general application process, the status of the application, or general Reg A regulation-related information. Rialto Markets LLC may direct applicants to specific sections of the Offering Statement to locate information or answers to their inquiry but does not opine or provide guidance on Issuer-related matters.

The offering will be made only by means of an offering circular. An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement which only means that the company may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. The securities offered by the company are highly speculative. Investing in shares of common stock of the company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. You may obtain a copy of the Form 1-A offering circular that is part of said offering statement here. You should read the offering circular before making any investment. The offering materials and this letter may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements, which constitute forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

This investment involves a high degree of risk. This investment is suitable only for persons who can bear the economic risk for an indefinite period of time and who can afford to lose their entire investment. Furthermore, investors must understand that such investment is illiquid and is expected to continue to be illiquid for an indefinite period of time. No public market exists for the securities.

This information is presented only for the purpose of providing a general overview of clinical trials. These uses have not been approved by the U.S. Food and Drug Administration (FDA) or other regulatory authorities.